SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 8/22/2017 11:49:14 PM - Followers: 718 - Board type: Free - Posts Today: 0

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

 

COMPLETED/UPCOMING MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Initial Statement of Beneficial Ownership (3) 08/08/2017 04:18:08 PM
IPIX News: Annual Statement of Changes in Beneficial Ownership (5) 08/08/2017 04:17:33 PM
IPIX News: Annual Statement of Changes in Beneficial Ownership (5) 08/08/2017 04:17:00 PM
IPIX News: Annual Statement of Changes in Beneficial Ownership (5) 08/08/2017 04:16:36 PM
IPIX News: Current Report Filing (8-k) 07/13/2017 04:04:10 PM
PostSubject
#193431  Sticky Note Leo has done an outstanding job managing available biodoc 08/13/17 03:48:53 PM
#192669  Sticky Note TODAY 8-7-17 ---> Press Release: Innovation Pharmaceuticals Completes TheHound 08/07/17 08:24:08 AM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#190524  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets, Blogs sox040713 07/16/17 03:13:55 PM
#187089  Sticky Note Prurisol's Importance: data We are nearing the very DaubersUP 06/23/17 04:59:13 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#194334   Prurisol—Psoriasis: Interim Analysis of Phase 2b trial (3Q2017). The sox040713 08/22/17 11:49:14 PM
#194333   Biodoc of and/or 1oldpprof: georgejjl 08/22/17 11:43:56 PM
#194332   I'm most excited about the K-OC trial and sox040713 08/22/17 11:42:11 PM
#194331   So another trial site in New Hampshire has georgejjl 08/22/17 11:36:45 PM
#194330   Does water activates p53 too? I'm sure A*STAR sox040713 08/22/17 11:33:11 PM
#194329   There is every chance of great data in LilBigKahuna 08/22/17 11:25:18 PM
#194328   KarinCA was nice enough along time ago to DaubersUP 08/22/17 11:17:22 PM
#194327   Thanks. Should have read the protocol, again. Still, LilBigKahuna 08/22/17 11:13:30 PM
#194326   The most recent short interest is < 1% sox040713 08/22/17 11:13:29 PM
#194325   D-UP is correct. Not only is Kevetrin safe, TheHound 08/22/17 11:04:31 PM
#194324   K has not proven efficacy against cancer - Amatuer17 08/22/17 10:41:22 PM
#194323   Inclusion Criteria: Presence of non-target lesions that have TheHound 08/22/17 10:34:45 PM
#194322   Types of cervical biopsies LilBigKahuna 08/22/17 10:30:22 PM
#194321   Tumor biopsy can be done with a needle. Pepperchino 08/22/17 10:17:44 PM
#194320   Oncology drugs are extremely valuable. If K's DaubersUP 08/22/17 09:55:20 PM
#194319   I'm sorry, but K has proven @thus far DaubersUP 08/22/17 09:51:16 PM
#194316   ok if the clint can pay the Giovanni 08/22/17 09:37:58 PM
#194315   FINRA short sales of IPIX AlanC 08/22/17 09:31:27 PM
#194314   JnJ has enormous cash and they can buy Amatuer17 08/22/17 09:22:04 PM
#194313   He is a master at it!;) Jhawker 08/22/17 09:19:41 PM
#194312   Creating false expectations is one of Scottsmith's specialties. "He thefamilyman 08/22/17 08:44:38 PM
#194311   How about a collaboration? Maybe an upfront 50mm and DaubersUP 08/22/17 08:38:12 PM
#194310   means everything. down 90% last 3 years MXAMDUD 08/22/17 08:11:35 PM
#194309   a cash all buy out is the only MXAMDUD 08/22/17 08:10:44 PM
#194308   That's ominous. Eom scottsmith 08/22/17 08:10:35 PM
#194307   redwing992006 There are many other factors involved and time Echo20 08/22/17 07:58:09 PM
#194306   It's a very well respected Ivy league hospital. Jhawker 08/22/17 07:51:56 PM
#194305   yes - interesting, as many other factors could redwing992006 08/22/17 07:20:43 PM
#194303   that is what they get paid to do! Giovanni 08/22/17 07:05:00 PM
#194301   Management can defer their salaries forever, but the sox040713 08/22/17 06:50:06 PM
#194300   He Said the end of the third quarter. Jhawker 08/22/17 06:27:23 PM
#194299   Or recruitment is just that slow. But DaubersUP 08/22/17 06:12:41 PM
#194298   I would "assume" the first couple patients in DaubersUP 08/22/17 06:10:45 PM
#194297   False news. Remember a couple CC's ago scottsmith 08/22/17 06:03:20 PM
#194294   Amatuer17 When JnJ and K were discussed in last Echo20 08/22/17 05:22:46 PM
#194293   WOW sells today vs buys almost 10 to JTORENCE 08/22/17 05:21:14 PM
#194292   He already advised you that it would be Jhawker 08/22/17 05:20:47 PM
#194291   "year to date" measurement means nothing. 123tom 08/22/17 05:13:57 PM
#194290   scottsmith the way you summed up your post JTORENCE 08/22/17 05:06:23 PM
#194289   maxdud These are the DOG DAYS OF SUMMER and Echo20 08/22/17 04:58:56 PM
#194288   As my post plainly stated, I advised Leo scottsmith 08/22/17 04:45:55 PM
#194286   Is that what he said? Or just DaubersUP 08/22/17 04:37:50 PM
#194285   I emailed Uncle Leo today and delivered to scottsmith 08/22/17 04:33:34 PM
#194284   If they have no credibility then why did Jhawker 08/22/17 04:17:39 PM
#194283   Agreed. (EOM) tons of misinformation going on. sox040713 08/22/17 04:09:02 PM
#194282   The fundamentals are the science. It's all about Jhawker 08/22/17 04:08:32 PM
#194281   IPIX mgmt has no credibility. They over MXAMDUD 08/22/17 04:00:51 PM
#194280   Great summary, sox040713   Blue Fin 08/22/17 03:54:10 PM
#194279   Well because, IMHO, IPIX (CTIX) needed more than TheBunny 08/22/17 03:41:32 PM
#194278   why would anyone sell if the news is MXAMDUD 08/22/17 03:38:03 PM
PostSubject